LTRN Strangle Strategy
LTRN (Lantern Pharma Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities.
LTRN (Lantern Pharma Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $49.3M, a beta of 2.33 versus the broader market, a 52-week range of 1.11-5.744, average daily share volume of 717K, a public-listing history dating back to 2020, approximately 24 full-time employees. These structural characteristics shape how LTRN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.33 indicates LTRN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on LTRN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LTRN snapshot
As of June 30, 2026, spot at $4.19, ATM IV 99.20%, IV rank 19.90%, expected move 28.44%. The strangle on LTRN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on LTRN specifically: LTRN IV at 99.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a LTRN strangle, with a market-implied 1-standard-deviation move of approximately 28.44% (roughly $1.19 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LTRN expiries trade a higher absolute premium for lower per-day decay. Position sizing on LTRN should anchor to the underlying notional of $4.19 per share and to the trader's directional view on LTRN stock.
LTRN strangle setup
The LTRN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LTRN near $4.19, the first option leg uses a $4.40 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LTRN chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LTRN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.40 | N/A |
| Buy 1 | Put | $3.98 | N/A |
LTRN strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LTRN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LTRN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on LTRN
Strangles on LTRN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LTRN chain.
LTRN thesis for this strangle
The market-implied 1-standard-deviation range for LTRN extends from approximately $3.00 on the downside to $5.38 on the upside. A LTRN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LTRN IV rank near 19.90% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LTRN at 99.20%. As a Healthcare name, LTRN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LTRN-specific events.
LTRN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LTRN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LTRN alongside the broader basket even when LTRN-specific fundamentals are unchanged. Always rebuild the position from current LTRN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LTRN?
- A strangle on LTRN is the strangle strategy applied to LTRN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LTRN stock trading near $4.19, the strikes shown on this page are snapped to the nearest listed LTRN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LTRN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LTRN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 99.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LTRN strangle?
- The breakeven for the LTRN strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LTRN market-implied 1-standard-deviation expected move is approximately 28.44%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LTRN?
- Strangles on LTRN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LTRN chain.
- How does current LTRN implied volatility affect this strangle?
- LTRN ATM IV is at 99.20% with IV rank near 19.90%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.